EYEGATE PHARMACEUTICALS INC·4

Feb 3, 9:50 PM ET

Obermayr Franz 4

4 · EYEGATE PHARMACEUTICALS INC · Filed Feb 3, 2021

Insider Transaction Report

Form 4
Period: 2021-02-01
Obermayr Franz
Acting CEO
Transactions
  • Award

    Stock Option (right to buy)

    2021-02-01+30,00030,000 total
    Exercise: $6.46Exp: 2031-02-01Common Stock (30,000 underlying)
Footnotes (1)
  • [F1]The reporting person received an Option to purchase Common Stock from the Issuer pursuant to the Issuer's 2014 Equity Incentive Plan. The Option will become exercisable as to one-third (1/3) of the shares underlying the Option on February 1, 2022, and the remaining balance vests monthly on the first day of each calendar month thereafter for a period of two years.

Documents

1 file
  • 4
    tm215262-2_4seq1.xmlPrimary

    OWNERSHIP DOCUMENT